miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathwayMarijn T. M. van Jaarsveld(Max Planck Institute for Molecular Genetics), Erik A.C. Wiemer(Erasmus MC Cancer Institute)Molecular CancerNovember 17, 201510.1186/s12943-015-0464-4Cited by 77SaveCiteExport RISWatch citationsRelated PapersMicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma|PLoS ONE|2020|4